Oliver Engert Acquires 1,200 Shares of Enovis (NYSE:ENOV) Stock

Enovis Corporation (NYSE:ENOV) insider Oliver Engert purchased 1,200 shares of the company’s stock in a transaction on Thursday, June 11th. The shares were bought at an average cost of $21.62 per share, with a total value of $25,944.00. Following the transaction, the insider directly owned 51,840 shares of the company’s stock, valued at $1,120,780.80. This represents a 2.37% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.

Oliver Engert also recently made the following trade(s):

• On Monday, June 15th, Oliver Engert purchased 1,000 shares of Enovis stock. The shares were bought at an average cost of $20.92 per share, with a total value of $20,920.00.
• On Wednesday, June 10th, Oliver Engert purchased 1,000 shares of Enovis stock. The shares were bought at an average cost of $23.00 per share, with a total value of $23,000.00.
• On Monday, June 1st, Oliver Engert purchased 1,000 shares of Enovis stock. The shares were bought at an average cost of $22.22 per share, with a total value of $22,220.00.

Enovis Stock Performance

Enovis stock opened at $21.56 on Wednesday. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.05 and a current ratio of 2.04. The stock has a fifty day moving average of $23.97 and a two-hundred day moving average of $24.44. The company has a market capitalization of $1.24 billion, a price-to-earnings ratio of -1.08 and a beta of 1.38. Enovis Corporation has a fifty-two week low of $20.55 and a fifty-two week high of $36.82.

Enovis (NYSE:ENOV) last released its quarterly earnings results on Thursday, May 7th. The company reported $0.89 earnings per share for the quarter, topping the consensus estimate of $0.82 by $0.07. The company had revenue of $589.15 million during the quarter, compared to the consensus estimate of $572.02 million. Enovis had a positive return on equity of 10.32% and a negative net margin of 49.92%.Enovis’s revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.81 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, analysts anticipate that Enovis Corporation will post 3.65 EPS for the current fiscal year.

Institutional Investors Weigh In On Enovis

Hedge funds and other institutional investors have recently made changes to their positions in the business. Arax Advisory Partners purchased a new stake in shares of Enovis in the fourth quarter valued at $29,000. EverSource Wealth Advisors LLC grew its position in Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after acquiring an additional 707 shares during the period. GAMMA Investing LLC grew its position in Enovis by 353.5% during the fourth quarter. GAMMA Investing LLC now owns 1,855 shares of the company’s stock valued at $49,000 after acquiring an additional 1,446 shares during the period. Danske Bank A S purchased a new stake in Enovis during the third quarter valued at about $64,000. Finally, iSAM Funds UK Ltd purchased a new stake in Enovis during the third quarter valued at about $80,000. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ENOV. Weiss Ratings reissued a “sell (e+)” rating on shares of Enovis in a research report on Friday, April 10th. BTIG Research reaffirmed a “buy” rating and issued a $39.00 price objective on shares of Enovis in a research report on Friday, May 22nd. Wall Street Zen downgraded Enovis from a “buy” rating to a “hold” rating in a research report on Saturday, June 6th. Needham & Company LLC lifted their price objective on Enovis from $49.00 to $52.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Finally, Zacks Research downgraded Enovis from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 1st. Seven research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Enovis has an average rating of “Moderate Buy” and a consensus target price of $44.50.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.